Minneapolis, MN, May 05, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP System, a proprietary platform designed to improve the clinical outcomes of electrophysiology procedures, today announced that the company will present at the Drexel Hamilton Micro Cap Investor Forum held on May 12, 2016 at Drexel Hamilton's office at 77 Water Street, Second Floor in Lower Manhattan.
The event will bring together institutional investors and emerging, high growth-potential companies. Institutional investors will have the opportunity to learn more about each of the 50 companies highlighted at the event. The conference will provide companies with a 30-minute time slot to present to an audience of investors and industry professionals. Management will also be available for one-on-one meetings with institutional investors.
BioSig Technologies is scheduled to present at 11:30am ET in Track C. During the presentation, Kenneth Londoner, BioSig Executive Chairman will update the investment community on the Company’s recent operational achievements as well as objectives for the next twelve months. To arrange a one-on-one meeting, please contact Brian McLaughlin, VP of Corporate Finance and Investor Relations at firstname.lastname@example.org or call (917) 370-9817.
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) (biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System.
The PURE EP System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig has partnered with Minnetronix on technology development and is working toward a FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center; and, has performed pre-clinical studies at Mayo Clinic in Minnesota. Additionally, an Advanced Research Program at Mayo Clinic will launch in June 2016. The Company is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio and Mount Sinai Medical Center in New York.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
Contact: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. email@example.com 917-370-9817
Source:BioSig Technologies, Inc.